Sws Partners Vertex Pharmaceuticals Inc Transaction History

Sws Partners

$310 Million
Q3 2024

A detailed history of Sws Partners transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Sws Partners holds 3,247 shares of VRTX stock, worth $1.63 Million. This represents 0.49% of its overall portfolio holdings.

Number of Shares

3,247

Previous 3,609 10.03%

Holding current value

$1.63 Million

Previous $1.69 Million 10.7%

% of portfolio

0.49%

Previous 0.51%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 15, 2024	SELL	$460.0 - $505.78 $166,520 - $183,092	-362 Reduced 10.03%	3,247 $1.51 Million
Q2 2024 Jul 17, 2024	SELL	$392.81 - $485.53 $289,500 - $357,835	-737 Reduced 16.96%	3,609 $1.69 Million
Q1 2024 Apr 30, 2024	SELL	$407.69 - $446.08 $22,830 - $24,980	-56 Reduced 1.27%	4,346 $1.82 Million
Q4 2023 Feb 13, 2024	SELL	$343.0 - $410.68 $24,696 - $29,568	-72 Reduced 1.61%	4,402 $1.79 Million
Q3 2023 Nov 09, 2023	SELL	$338.18 - $362.46 $376,732 - $403,780	-1,114 Reduced 19.94%	4,474 $1.56 Million
Q2 2023 Aug 17, 2023	BUY	$314.42 - $351.91 $1.76 Million - $1.97 Million	5,588 New	5,588 $1.97 Million
Q2 2023 Jul 26, 2023	SELL	$314.42 - $351.91 $18,865 - $21,114	-60 Reduced 1.06%	5,588 $1.97 Million
Q1 2023 May 09, 2023	BUY	$283.23 - $323.1 $1.6 Million - $1.82 Million	5,648 New	5,648 $1.78 Million
Q3 2022 Nov 09, 2022	BUY	$273.83 - $305.53 $7,667 - $8,554	28 Added 0.5%	5,592 $1.62 Million
Q2 2022 Jul 28, 2022	BUY	$234.96 - $292.55 $2,584 - $3,218	11 Added 0.2%	5,564 $1.57 Million
Q1 2022 May 05, 2022	SELL	$221.42 - $260.97 $952,991 - $1.12 Million	-4,304 Reduced 43.66%	5,553 $1.45 Million
Q4 2021 Jan 25, 2022	BUY	$177.01 - $223.45 $443,941 - $560,412	2,508 Added 34.13%	9,857 $2.17 Million
Q3 2021 Nov 08, 2021	BUY	$181.39 - $202.99 $24,487 - $27,403	135 Added 1.87%	7,349 $1.33 Million
Q2 2021 Aug 09, 2021	BUY	$187.49 - $221.1 $26,248 - $30,954	140 Added 1.98%	7,214 $1.46 Million
Q1 2021 May 17, 2021	BUY	$207.02 - $241.31 $680,888 - $793,668	3,289 Added 86.9%	7,074 $1.52 Million
Q4 2020 Mar 31, 2021	BUY	$207.01 - $276.09 $213,220 - $284,372	1,030 Added 37.39%	3,785 $895,000
Q3 2020 Nov 13, 2020	BUY	$255.65 - $303.1 $76,439 - $90,626	299 Added 12.17%	2,755 $750,000
Q2 2020 Aug 13, 2020	BUY	$225.48 - $295.8 $58,850 - $77,203	261 Added 11.89%	2,456 $668,000
Q1 2020 May 14, 2020	BUY	$199.77 - $247.81 $116,266 - $144,225	582 Added 36.08%	2,195 $522,000
Q3 2019 Nov 21, 2019	SELL	$166.23 - $187.09 $4.74 Million - $5.33 Million	-28,505 Reduced 94.64%	1,613 $337,000
Q3 2019 Nov 15, 2019	BUY	$166.23 - $187.09 $4.71 Million - $5.3 Million	28,327 Added 1581.63%	30,118 $5.27 Million
Q2 2019 Aug 13, 2019	BUY	$164.61 - $190.37 $63,210 - $73,102	384 Added 27.29%	1,791 $319,000
Q4 2018 Feb 04, 2019	SELL	$151.91 - $192.21 $20,052 - $25,371	-132 Reduced 8.58%	1,407 $233,000
Q3 2018 Nov 14, 2018	BUY	$167.73 - $192.74 $258,136 - $296,626	1,539 New	1,539 $297,000

Others Institutions Holding VRTX

# of Institutions

1,716

Shares Held

225M

Call Options Held

1.19M

Put Options Held

1.56M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $129B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Sws Partners, based on Form 13F filings with the SEC.

News

Stay updated on Sws Partners with notifications on news.

Account